Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL1319072 | 0.93 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL6724769 | 0.78 | TSHR (0.35) | TSHR | |
| SCHEMBL530219 | 0.78 | TSHR (0.35) | TSHR | |
| SCHEMBL530220 | 0.76 | TSHR (0.33) | TSHR | |
| SCHEMBL22325533 | 0.76 | TSHR (0.52) | TSHRCHRM2CHRM4CHRM1MAPT | |
| SCHEMBL7787116 | 0.76 | TSHR (0.33) | TSHR | |
| SCHEMBL4191590 | 0.75 | — | — | |
| SCHEMBL467571 | 0.75 | LMNA (0.39) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL4186678 | 0.75 | — | — | |
| SCHEMBL26980836 | 0.75 | CHRM2 (0.30) | LMNATSHRCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411376-A1 | A PROCESS FOR THE PREPARATION OF PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | Lupin Limited (IN) | 2018-12-12 | — | — | EP | claimed |
| WO-2017134607-A1 | A PROCESS FOR THE PREPARATION OF PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | LUPIN LIMITED (IN) | 2017-08-10 | — | — | WO | claimed |
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN S A U (ES) | 2026-05-21 | — | — | US | disclosed |
| EP-4741399-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | President And Fellows Of Harvard College (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | CURIA SPAIN, S.A.U. (ES) | 2026-02-17 | — | — | US | disclosed |
| EP-3664799-B1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | HARVARD COLLEGE (US) | 2025-10-01 | — | — | EP | disclosed |
| CN-115151529-B | Processes and intermediates for preparing Wu Pati n | 库里亚西班牙公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-4452933-A1 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | Massachusetts Institute of Technology (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4359380-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE | Celgene Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4340859-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | Biohaven Therapeutics Ltd. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003067286-A2 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS, LLC (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0043630-B1 | IMPROVED PROCESS FOR THE SILYLATION OF ORGANIC COMPOUNDS WITH 1,1,1-TRIMETHYL-N-(TRIMETHYLSILYL)SILANAMINE BY MEANS OF CATALYSIS WITH CERTAIN NITROGEN CONTAINING COMPOUNDS | GIST-BROCADES N.V. (NL) | 1986-01-08 | — | — | EP | disclosed |
| US-4284766-A | Process for the preparation of cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1981-08-18 | — | — | US | disclosed |
| US-4258183-A | Process for the preparation of cephalosporin compounds | GLAXO GROUP LIMITED (GB) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | JAK1, JAK3, JAK2 | LMNA 750/4885TSHR 624/4885CHRM2 3173/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | LMNA 4320/4885TSHR 247/4885CHRM2 222/4885 |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | JAK1, JAK3, MET | LMNA 602/4885TSHR 756/4885CHRM2 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.